A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 May 2018 Planned End Date changed from 28 Feb 2018 to 2 Dec 2019.
- 09 May 2018 Planned primary completion date changed from 28 Feb 2018 to 2 Dec 2019.
- 30 Jan 2018 Planned End Date changed from 28 Dec 2017 to 28 Feb 2018.